Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats

Xu,Xue; Zhang,Lei; Liang,Jiangjiu

doi:10.3892/mmr.2013.1548

Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats

Authors:
- Xue Xu
- Lei Zhang
- Jiangjiu Liang
View Affiliations

Affiliations: Department of Health Care, Shandong Provincial Qianfoshan Hospital, Affiliated Hospital of Shandong University, Shandong University, Jinan, Shandong 250014, P.R. China, Department of Orthopedics, Shandong Provincial Qianfoshan Hospital, Affiliated Hospital of Shandong University, Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: June 25, 2013 https://doi.org/10.3892/mmr.2013.1548
Pages: 385-392

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pressure overload‑induced myocardial hypertrophy is associated with a poor prognosis in humans and contributes to the development of cardiac arrhythmias, diastolic dysfunction and ultimate congestive heart failure. 3‑Hydroxy‑3‑methylglutaryl‑CoA (HMG‑CoA) reductase inhibitors, also known as statins, have been previously shown to induce regression of myocardial hypertrophy in aortic banding models. However, there is limited knowledge regarding the underlying molecular mechanisms. Therefore, we hypothesized that the myocardial hypertrophy‑related signaling pathways protein kinase B (Akt), extracellular signal‑regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Therefore, the above‑mentioned activation pathways were hypothesized to be involved in the regression of pressure overload‑induced myocardial hypertrophy treated by RSV. Twenty‑eight Wistar rats were randomly allocated into 4 groups: the sham operation‑vehicle (SH‑V), abdominal aortic constriction‑vehicle (AAC‑V), abdominal aortic constriction‑RSV 10 mg/kg/day (AAC‑LO) and the abdominal aortic constriction‑RSV 20 mg/kg/day (AAC‑HI) group. Following the establishment of the abdominal aorta constriction model, we investigated the effect of RSV, a new hydrophilic statin, on abdominal aortic constriction‑induced myocardial hypertrophy as well as the underlying intercellular signaling pathways after 5 days and 4 weeks of drug intervention. Moreover, echocardiographic features and the left ventricular weight to final body weight ratio (LVW/BW) were determined. Cross‑sectional areas (CSAs) of cardiomyocytes were assessed by hematoxylin and eosin (H&E) staining. Atrial natriuretic factor (ANF), β‑myosin heavy chain (β‑MHC) and peroxisome proliferator‑activated receptor α (PPARα) messenger RNA (mRNA) expression was assessed using RT‑PCR. The phosphorylation of Akt, ERK1/2 and GATA4 were also examined using western blot analysis. Our results showed that RSV significantly attenuates pressure overload‑induced myocardial hypertrophy by preventing myocardial hypertrophy‑related activation of Akt, ERK1/2 and GATA4 signaling pathways.

View Figures

View References

1	Levy D, Garrison RJ, Savage DD, Kannel WB and Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1561–1566. 1990. View Article : Google Scholar : PubMed/NCBI
2	Okin PM, Devereux RB, Jern S, et al: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 292:2343–2349. 2004. View Article : Google Scholar : PubMed/NCBI
3	Auer J, Berent R, Weber T and Eber B: Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr Med Chem. 9:1831–1850. 2002. View Article : Google Scholar : PubMed/NCBI
4	Laufs U, Fata VL and Liao JK: Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 272:31725–31729. 1997. View Article : Google Scholar : PubMed/NCBI
5	Fukumoto Y, Libby P, Rabkin E, et al: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 103:993–999. 2001. View Article : Google Scholar : PubMed/NCBI
6	Ridker PM, Rifai N, Clearfield M, et al: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:1959–1965. 2001. View Article : Google Scholar
7	Planavila A, Laguna JC and Vázquez-Carrera M: Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim Biophys Acta. 1687:76–83. 2005. View Article : Google Scholar
8	Young ME, Laws FA, Goodwin GW and Taegtmeyer H: Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem. 276:44390–44395. 2001. View Article : Google Scholar : PubMed/NCBI
9	Takemoto M, Node K, Nakagami H, et al: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 108:1429–1437. 2001. View Article : Google Scholar : PubMed/NCBI
10	Kameda Y, Hasegawa H, Kubota A, et al: Effects of pitavastatin on pressure overload-induced heart failure in mice. Circ J. 76:1159–1168. 2012. View Article : Google Scholar : PubMed/NCBI
11	Xu R, Lin F, Zhang S, Chen X, Hu S and Zheng Z: Signal pathways involved in reverse remodeling of the hypertrophic rat heart after pressure unloading. Int J Cardiol. 143:414–423. 2010. View Article : Google Scholar : PubMed/NCBI
12	Esposito G, Prasad SV, Rapacciuolo A, Mao L, Koch WJ and Rockman HA: Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase kinase activity in in vivo pressure overload. Circulation. 103:1453–1458. 2001. View Article : Google Scholar
13	van Berlo JH, Elrod JW, Aronow BJ, Pu WT and Molkentin JD: Serine 105 phosphorylation of transcription factor GATA4 is necessary for stress-induced cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 108:12331–12336. 2011.PubMed/NCBI
14	Siri FM: Chronic norepinephrine infusion and adrenergic function of hypertrophied hearts. Am J Physiol. 248(4 Pt 2): H485–H492. 1985.PubMed/NCBI
15	Teichholz LE, Kreulen T, Herman MV and Gorlin R: Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 37:7–11. 1976.
16	Leskinen H, Rauma-Pinola T, Szokodi I, et al: Adaptive or maladaptive response to adenoviral adrenomedullin gene transfer is context-dependent in the heart. J Gene Med. 10:867–877. 2008. View Article : Google Scholar : PubMed/NCBI
17	Woodiwiss AJ, Tsotetsi OJ, Sprott S, et al: Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation. 103:155–160. 2001. View Article : Google Scholar : PubMed/NCBI
18	Hong Y, Hui SC, Chan TY and Hou JY: Effect of berberine on regression of pressure-overload induced cardiac hypertrophy in rats. Am J Chin Med. 30:589–599. 2002. View Article : Google Scholar : PubMed/NCBI
19	Ni L, Zhou C, Duan Q, et al: β-AR blockers suppresses ER stress in cardiac hypertrophy and heart failure. PLoS One. 6:e272942011.
20	Li J, Li P, Feng X, et al: Effects of losartan on pressure overload-induced cardiac gene expression profiling in rats. Clin Exp Pharmacol Physiol. 30:827–832. 2003. View Article : Google Scholar : PubMed/NCBI
21	Zhou MS, Jaimes EA and Raij L: Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension. 44:186–190. 2004. View Article : Google Scholar
22	Takayama N, Kai H, Kudo H, et al: Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways. Hypertens Res. 34:341–347. 2011. View Article : Google Scholar : PubMed/NCBI
23	Habibi J, Whaley-Connell A, Qazi MA, et al: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology. 148:2181–2188. 2007. View Article : Google Scholar : PubMed/NCBI
24	Choi EY, Chang W, Lim S, et al: Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh. Eur J Pharmacol. 627:56–62. 2010. View Article : Google Scholar : PubMed/NCBI
25	Chang SA, Kim YJ, Lee HW, et al: Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension. 54:591–597. 2009. View Article : Google Scholar : PubMed/NCBI
26	Chaanine AH and Hajjar RJ: AKT signalling in the failing heart. Eur J Heart Fail. 13:825–829. 2011. View Article : Google Scholar : PubMed/NCBI
27	Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE and Molkentin JD: The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol. 21:7460–7469. 2001. View Article : Google Scholar : PubMed/NCBI
28	Tenhunen O, Sármán B, Kerkelä R, et al: Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart. J Biol Chem. 279:24852–24860. 2004. View Article : Google Scholar : PubMed/NCBI
29	Condorelli G, Drusco A, Stassi G, et al: Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA. 99:12333–12338. 2002. View Article : Google Scholar : PubMed/NCBI
30	Morisco C, Seta K, Hardt SE, Lee Y, Vatner SF and Sadoshima J: Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J Biol Chem. 276:28586–28597. 2001. View Article : Google Scholar : PubMed/NCBI
31	Smeets PJ, Teunissen BE, Willemsen PH, et al: Cardiac hypertrophy is enhanced in PPAR alpha−/− mice in response to chronic pressure overload. Cardiovasc Res. 78:79–89. 2008.
32	Miyamoto T, Takeishi Y, Takahashi H, et al: Activation of distinct signal transduction pathways in hypertrophied hearts by pressure and volume overload. Basic Res Cardiol. 99:328–337. 2004.PubMed/NCBI
33	Yang D, Ma S, Tan Y, et al: Adrenergic receptor blockade-induced regression of pressure-overload cardiac hypertrophy is associated with inhibition of the calcineurin/NFAT3/GATA4 pathway. Mol Med Rep. 3:497–501. 2010. View Article : Google Scholar : PubMed/NCBI